ACETAMINOPHEN WITH CODEINE - CAPLET 300 MG
ACETAMINOPHEN : 300 MG CODEINE PHOSPHATE : 8 MG CAFFEINE : 15 MG · DIN 02143933 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is ACETAMINOPHEN WITH CODEINE - CAPLET?
ACETAMINOPHEN WITH CODEINE - CAPLET 300 MG contains ACETAMINOPHEN : 300 MG CODEINE PHOSPHATE : 8 MG CAFFEINE : 15 MG. It is listed in the Health Canada Drug Product Database under DIN 02143933, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Jan-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACETAMINOPHEN WITH CODEINE - CAPLET used for?
Indicated for the short-term relief of mild to moderate pain in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is ACETAMINOPHEN WITH CODEINE - CAPLET called?
The same molecule, CODEINE AND PARACETAMOL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Brunacod | Latin | South Africa |
| Ibupain Forte | Latin | South Africa |
| Spectrapain | Latin | South Africa |
| Codef Cough | Latin | South Africa |
| Docsed | Latin | South Africa |
| Lenazine Forte | Latin | South Africa |
| Mybucod | Latin | South Africa |
| Suncodin Tablets | Latin | South Africa |
| ACTIFED COMPOUND LINCTUS | Latin | Saudi Arabia |
| Adco-Kiddipayne | Latin | South Africa |
| Adco-Metaxol | Latin | South Africa |
| AstraPain Syrup | Latin | South Africa |
| Ban Pain A/F | Latin | South Africa |
| Codeine | Latin | South Africa |
| CODETUX AD | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02143933 |
|---|---|
| Brand name | ACETAMINOPHEN WITH CODEINE - CAPLET |
| Generic / active ingredient | ACETAMINOPHEN : 300 MG CODEINE PHOSPHATE : 8 MG CAFFEINE : 15 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AJ06 CODEINE AND PARACETAMOL |
| AHFS class | 28:08.08 ; 28:08.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Jan-2014 |
| Original market date | 1997-10-28 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02143933 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2143933 |
| Brand name | ACETAMINOPHEN WITH CODEINE - CAPLET |
| Active ingredient / INN | ACETAMINOPHEN : 300 MG CODEINE PHOSPHATE : 8 MG CAFFEINE : 15 MG |
| ATC code | N02AJ06 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02 |
| AHFS class | 28:08.08 ; 28:08.92 |
| Health Canada schedule | NARCOTICS (CDSA I) |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it administered?
Adults: 1 or 2 caplets every 4 hours as required, not to exceed 12 caplets in 24 hours. Use lowest effective dose for shortest duration. Swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store securely to avoid theft or misuse. (Specific temperature range not in snippet, refers to STORAGE AND STABILITY section).
How is it supplied?
Not explicitly detailed in the provided text snippet (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section).
Which pack is which?
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | Not explicitly detailed in the provided text snippet (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section). |
| Storage | Store securely to avoid theft or misuse. (Specific temperature range not in snippet, refers to STORAGE AND STABILITY section). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; GI obstruction; suspected surgical abdomen; mild pain; asthma/COPD; respiratory depression; alcoholism; CNS depression; head injury; severe hepatic/renal impairment; children <18.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and fatal respiratory depression. Do not use with alcohol. Risk of death in CYP2D6 ultra-rapid metabolizers. Hepatotoxicity with acetaminophen.
Is CODEINE AND PARACETAMOL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PURDUE PHARMA, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02AJ06 CODEINE AND PARACETAMOL. 9 of 66 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE TABLETS | 300 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02154234 |
| PMS-ACETAMINOPHEN WITH CODEINE ELIXIR | 8 MG / 5 ML | ELIXIR | PHARMASCIENCE INC | MARKETED | DIN 00816027 |
| TEVA-EMTEC-30 | 30 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00608882 |
| TEVA-LENOLTEC NO. 1 | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00653233 |
| TEVA-LENOLTEC NO. 2 | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00653241 |
| TEVA-LENOLTEC NO. 3 | 300 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00653276 |
| TEVA-LENOLTEC NO. 4 | 60 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00621463 |
| TRIATEC-30 | 300 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 00789828 |
| (EXTRA STRENGTH) ACETAMINOPHEN, CAFFEINE & 8MG CODEINE PHOSPHATE CAPLETS | 15 MG | TABLET | STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | CANCELLED POST MARKET | DIN 02236871 |
| ACET 2 | 15 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00706515 |
Who else supplies CODEINE AND PARACETAMOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CODEINE AND PARACETAMOL appears in 25 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CODEINE AND PARACETAMOL cost around the world?
CODEINE AND PARACETAMOL is listed on 7 national price registers Nexara tracks, across 65 pack listings published on 7 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 31 | 42 | 01 Sep 2026 |
| Morocco | PPV (public price) | 6 | 6 | 05 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
| United States | acquisition | 3 | 5 | 03 Sep 2026 |
| Australia | ex-manufacturer | 1 | 4 | 08 Sep 2026 |
| Hungary | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
| Saudi Arabia | public | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.